Capricor Therapeutics Inc's fundamentals are relatively weak, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 155 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 53.90.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Capricor Therapeutics Inc is 5.67, ranking 336 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 323.95%.
Key Metrics
The current valuation score of Capricor Therapeutics Inc is 5.77, ranking 360 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.79, which is -81.61% below the recent high of -2.35 and -67.59% above the recent low of -21.43.
The current earnings forecast score of Capricor Therapeutics Inc is 8.40, ranking 129 out of 391 in the Biotechnology & Medical Research industry. The average price target is 47.50, with a high of 62.00 and a low of 20.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Capricor Therapeutics Inc is 7.37, ranking 54 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 35.23 and the support level at 23.82, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Capricor Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.00%, representing a quarter-over-quarter decrease of 13.89%. The largest institutional shareholder is The Vanguard, holding a total of 2.56M shares, representing 4.45% of shares outstanding, with 9.75% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Capricor Therapeutics Inc is 1.37, ranking 316 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Capricor Therapeutics Inc’s latest ESG disclosure is at an average level in the Biotechnology & Medical Research industry, showing no material impact on overall risk.
